title: Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum.
abstract: OBJECTIVE
  To characterize imatinib's effect on endometrial stromal cell (ESC) attachment, proliferation, and invasion in modeled peritoneum.
  
  
  METHODS
  In vitro study.
  
  
  METHODS
  Academic medical center.
  
  
  METHODS
  Twelve normally cycling women.
  
  
  METHODS
  Imatinib treatment in ESCs from women without endometriosis.
  
  
  METHODS
  Rate of ESC attachment, proliferation, and invasion.
  
  
  RESULTS
  Imatinib treatment at 10 μM had no effect on ESC attachment. Treatment with 0.5 μM, 2 μM, and 10 μM of imatinib reduced ESC proliferation by 30%, 72%, and 76%, respectively. The 0.1 μM dose of imatinib had no effect on proliferation. Treatment with 5 μM and 10 μM of imatinib reduced ESC invasion by 30% and 73%, respectively. The 2 μM dose had no effect on invasion.
  
  
  CONCLUSIONS
  Imatinib treatment reduces ESC proliferation and invasion in modeled peritoneum without altering attachment. Imatinib may have a therapeutic role in endometriosis treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA. jgriffith@hfi-ivf.com
authors.forename: Jason S
authors.initials: JS
authors.lastname: Griffith
authors.forename: Peter A
authors.initials: PA
authors.lastname: Binkley
authors.forename: Namir B
authors.initials: NB
authors.lastname: Kirma
authors.forename: Robert S
authors.initials: RS
authors.lastname: Schenken
authors.forename: Craig A
authors.initials: CA
authors.lastname: Witz
authors.forename: Rajeshwar R
authors.initials: RR
authors.lastname: Tekmal
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D018929:Cell Culture Techniques; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008954:Models, Biological; D010537:Peritoneum / Q000187:drug effects* / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D017154:Stromal Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D057705:Transendothelial and Transepithelial Migration / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate